Jia Wu, Ph.D., and colleagues at MD Anderson Cancer Center have developed a machine learning model called "A-STEP" that predicts whether a patient is likely to benefit more from combination therapy or monotherapy. #lungcancer buff.ly/ScD23PH

Great insights from our friend Dr. Jacob Sands from Dana-Farber Cancer Institute. Dr. Sands joined Targeted Oncology to talk about the FDA’s accelerated approval of datopotamab deruxtecan (Dato-DXd) in post-EGFR NSCLC treatment. #lungcancer buff.ly/xtaHUUO

Investigators have uncovered a promising new mechanism to improve treatment for small-cell lung cancer! #lungcancer buff.ly/1NP82En

Lung cancer care evolves fast, and uncertainty is inevitable. But our friend Dr. Narjust Florez of Dana-Farber Cancer Institute and Harvard Medical School is helping change how the thoracic oncology community responds. #lungcancer buff.ly/7cMZ1KY

New proteogenomic data from 400+ lung adenocarcinoma patients reveals nitrosamines may be driving poor outcomes in never-smokers at rates comparable to tobacco exposure. #lungcancer buff.ly/oD2MuJm

An interview with Dr. Julia Rotow of Dana-Farber Cancer Institute lays bare a persistent, under-recognized barrier to precision lung cancer. Fragmented health systems are delaying critical biomarker testing, and patients are paying the price. #lungcancer buff.ly/yOEGQa1

New research in Cancer Biology & Medicine presents a significant advance in overcoming chemoresistance in non-small cell lung cancer (NSCLC). #lungcancer buff.ly/JmWBeam

ALCMI consortium member Baptist Health's latest clinical data is changing surgical eligibility criteria for early-stage lung cancer patients, and the implications are significant. #lungcancer buff.ly/GNYUemW

A new study published in Thorax links higher consumption of ultraprocessed foods to increased risk of both NSCLC and SCLC, independent of smoking status and other known risk factors. #lungcancer buff.ly/igr8Ja4

A new therapy is emerging for KRAS-driven lung cancer that rewires the epigenome, not just the genome. #lungcancer buff.ly/i97rMis

New data from a dual-center cohort study may shift how we interpret β-catenin comutations in EGFR-mutant NSCLC. #lungcancer buff.ly/C5bbUK5

AstraZeneca has unveiled long-term data that could redefine how we treat EGFR-mutated non-small cell lung cancer across all stages. #lungcancer buff.ly/u7XsQvz

A new study out of Moffitt Cancer Center is reframing how we think about lung cancer outcomes by embedding care within the lived experiences of underserved communities. #lungcancer buff.ly/dIeLLCc

RB1 loss may silently set the stage for EGFR resistance before treatment even begins. #lungcancer buff.ly/REbKCpv

A new study shows that quantitative radiomic analysis of CT scans powered by machine learning and deep learning can accurately predict non-small cell lung cancer histological subtypes before surgery. #lungcancer buff.ly/KyEZKm9

A new study out of Tongji University and Nantong University may have just cracked a major problem in NSCLC treatment—how to simultaneously weaken tumor cells and restore immune function during chemotherapy. #lungcancer buff.ly/FUjlnoM

The FDA has granted accelerated approval to Boehringer Ingelheim's Hernexeos (zongertinib), the first oral therapy for adults with unresectable or metastatic HER2-mutant non-squamous NSCLC. #lungcancer buff.ly/E4IphzK

Lung cancer predictive models are promising tools for risk-stratifying pulmonary nodules, but most collapse when tested outside the environment where they were trained. #lungcancer bit.ly/4lnkWh5

A new tool from the American Cancer Society's National Lung Cancer Roundtable gives state and local leaders the data and strategies needed to increase screening rates and improve outcomes. #lungcancer buff.ly/dgjN8kZ

New genomic data from the Sherlock-Lung study is shining a light on lung cancer in never-smokers. #lungcancer buff.ly/ux6b5Wa